Omnicell, Inc. — Q3 2012 Form 10-Q
Business context and reporting period
Quarter ended September 30, 2012; filed November 8, 2012. Omnicell provides medication and medical-supply automation, related consumables and services to healthcare providers. Results include MedPak/MTS, acquired May 21, 2012, only from the acquisition date. The acquisition expanded the business into non-acute care medication-adherence packaging and created Acute Care and Non-Acute Care reporting segments, so year-over-year comparisons are not fully like-for-like.
Financial performance
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Revenue | $84.3 million | $64.4 million | $223.9 million | $182.6 million |
| Gross profit / margin | $46.1 million / 54.7% | $34.4 million / 53.4% | $121.2 million / 54.2% | $99.9 million / 54.7% |
| Operating income / margin | $11.2 million / 13.3% | $4.8 million / 7.4% | $17.3 million / 7.7% | $10.1 million / 5.5% |
| Net income | $6.9 million | $3.0 million | $10.6 million | $6.3 million |
| Diluted EPS | $0.20 | $0.09 | $0.31 | $0.18 |
- Q3 revenue rose 30.9% year over year; nine-month revenue rose 22.6%. In Q3, Non-Acute Care contributed $19.9 million of revenue, while Acute Care revenue was $64.4 million and approximately flat year over year.
- Q3 product revenue grew 35.5% and service and other revenue grew 15.3%. Q3 gross margin improved from the prior-year quarter, primarily reflecting favorable Acute Care product mix; nine-month gross margin was lower year over year.
- Q3 Non-Acute Care revenue and operating income were $19.9 million and $2.8 million; Acute Care revenue and operating income were $64.4 million and $8.4 million. Segment comparisons are affected by MTS being included only since May 21, 2012.
Cash, liquidity and balance sheet
- Cash and cash equivalents were $54.8 million at September 30, 2012, versus $191.8 million at year-end 2011; no short-term investments remained. Current assets were $166.5 million and current liabilities $78.6 million.
- Operating cash flow for the first nine months was $27.5 million, compared with $14.6 million a year earlier. Investing activities used $161.2 million, primarily reflecting $156.3 million of net cash paid for MTS; financing activities used $3.3 million, including $12.4 million of share repurchases, partly offset by employee-plan proceeds and tax benefits.
- The balance sheet reports no borrowings. Total liabilities were $125.5 million, including deferred tax liabilities and deferred revenue. Management said existing cash and operating cash flows should cover working capital and capital expenditure needs for at least 12 months, while noting future financing could be needed for broader needs or acquisitions.
Material changes, outlook and risks
- The MTS acquisition had preliminary consideration of approximately $159.8 million, including estimated working-capital adjustments. The allocation included $84.1 million of goodwill and $83.5 million of identifiable intangibles; the company said the allocation remained preliminary. MTS contributed approximately $18.3 million of Q3 revenue and $1.9 million of net income.
- Nine-month acquisition-related costs were approximately $3.2 million. Reported segment results also included inventory fair-value step-up and other acquisition-related charges.
- Management expected revenue to continue increasing in 2012 as orders were fulfilled and lease renewals continued, with reported growth also reflecting the newly consolidated Non-Acute Care business. It expected R&D spending to remain relatively flat as a percentage of revenue and SG&A to grow nominally, with efficiencies reducing SG&A relative to revenue growth. No specific numerical earnings or revenue guidance was provided.
- Key risks include healthcare customers delaying capital purchases, lengthy sales and installation cycles that defer revenue recognition, competition and pricing pressure, successful integration of MTS, and the ability to supply consumable medication packages on time. The filing also highlights supplier concentration, international currency and operating risks, and potential inventory obsolescence.
- Operating lease commitments totaled $47.1 million, including an approximately $40.0 million base commitment for the new Mountain View headquarters lease. Gross unrecognized tax benefits were approximately $8.4 million. Management reported no legal proceedings believed likely to have a material impact and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Whether MTS integration delivers expected growth and operational benefits, and how the preliminary purchase-price allocation or acquisition-related costs change.
- Whether cash generation and liquidity remain adequate after the acquisition, repurchases and new lease commitments.
- Whether Acute Care growth improves and Non-Acute Care margins develop as the acquired business is consolidated for full periods.
- Whether customer order timing, installation capacity and consumable supply support management’s stated revenue outlook.
- Potential cash or earnings effects from the uncertain tax positions and the company’s substantial long-term lease obligations.